Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors - Pipeline Insight, 2018

  • ID: 4382612
  • Drug Pipelines
  • 80 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • Acerta Pharma
  • GlaxoSmithKline
  • Incyte
  • Johnson & Johnson
  • Merck
  • Rhizen Pharmaceuticals
  • MORE
"Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors- Pipeline Insight, 2018" report outlays comprehensive Insight of present scenario and growth prospects across Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 15+ products along with 15+ companies involved.

Products covered by Phase
  • Phase III, Phase II and Phase I
  • Pre-clinical and Unknown
  • Inactive (Dormant)
Overview of pipeline development activities for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • Provides an overview of therapeutic pipeline activity for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant pipeline projects across Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acerta Pharma
  • GlaxoSmithKline
  • Incyte
  • Johnson & Johnson
  • Merck
  • Rhizen Pharmaceuticals
  • MORE
Overview: Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors
Introduction
Classes of PI3Ks
PI3K Isoforms
Role of PI3K δ in Normal and Disease States
Future Perspectives
Pipeline Therapeutics (Active Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Leniolisib: Novartis
Product Description
Research and Development
(The list continues)
Mid-Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical and Unknown Stage Products
Comparative Analysis
Dormant Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration

List of Tables:
Table 1: Total Products for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical Stage Products
Table 6: Dormant Products
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration

List of Figures:
Figure 1: Action of all the forms of PI3K signaling pathway inhibitors
Figure 2: Total Products for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors
Figure 3: Late Stage Products (Phase III)
Figure 4: Mid Stage Products (Phase II)
Figure 5: Early Stage Products (Phase I)
Figure 6: Pre-clinical Stage Products
Figure 7: Dormant Products
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • UCB
  • Acerta Pharma
  • Exelixix
  • GlaxoSmithKline
  • Hutchison MediPharma
  • Incyte
  • Incyte Corporation
  • Johnson & Johnson
  • MEI Pharma
  • Merck
  • Novartis
  • Rhizen Pharmaceuticals
  • SignalRx Pharmaceuticals
  • TargeGen
  • TG Therapeutics
  • Verastem
  • Xcovery
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll